Blinatumomab replaces chemotherapy cycles in high-risk childhood ALL

Design

Randomised controlled trial, planned interim analysis

Population

709 children with newly diagnosed high-risk B-cell ALL

Primary outcome

Event-free survival at four years

Effect

83.0% vs 70.3%; hazard ratio 0.51 (95% CI 0.35-0.73)

Intensive chemotherapy cures most children with B-cell acute lymphoblastic leukaemia but at a heavy toll of toxicity and infection. This randomised trial tested whether the bispecific T-cell engager blinatumomab could replace two cycles of that chemotherapy in high-risk disease, randomising 709 children after consolidation.

The result was a clear win. Estimated four-year event-free survival was 83.0% with blinatumomab versus 70.3% with chemotherapy, a hazard ratio of 0.51. The safety contrast was just as striking: treatment-related infection occurred in 23.9% with blinatumomab against 69.4% with chemotherapy, and life-threatening adverse events in 0.5% versus 4.7%. Grade 2 or higher cytokine release syndrome was rare at 1.1%, and neurotoxic events, though more common than with chemotherapy, were manageable.

The practical change is substantial: replacing two cycles of intensive chemotherapy with blinatumomab improved survival while sharply reducing infection and life-threatening toxicity in high-risk childhood B-ALL. This is an interim analysis, but the effect size and safety gain are large.

• Randomised trial in 709 children with newly diagnosed high-risk B-cell ALL.
• Two chemotherapy cycles were replaced with blinatumomab after consolidation.
• Four-year event-free survival was 83.0% versus 70.3% (hazard ratio 0.51).
• Treatment-related infection fell from 69.4% to 23.9%.
• Life-threatening adverse events were 0.5% versus 4.7%.

Why it matters

It overturns the assumption that intensive chemotherapy cycles are necessary, improving both survival and safety at once.

Don't overread it

This is a planned interim analysis at a median 2.9 years in a high-risk subgroup; longer follow-up will confirm the durability of the event-free survival gain.

The statistics, in plain English

A hazard ratio of 0.51 means roughly half the rate of relapse, second cancer or death, and the 83.0% versus 70.3% gap is both statistically robust (p=0.0002) and large in absolute terms. The fall in infection from 69% to 24% is the kind of difference families feel directly.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.